Location of Repository

Liposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potential

By Eva W Stratford, Russell Castro, Anna Wennerstrøm, Ruth Holm, Else Munthe, Silje Lauvrak, Bodil Bjerkehagen and Ola Myklebost

Abstract

Aldehyde dehydrogenase (ALDH) has recently been shown to be a marker of cancer stem-like cells (CSCs) across tumour types. The primary goals of this study were to investigate whether ALDH is expressed in liposarcomas, and whether CSCs can be identified in the ALDHhigh subpopulation. We have demonstrated that ALDH is indeed expressed in 10 out of 10 liposarcoma patient samples. Using a liposarcoma xenograft model, we have identified a small population of cells with an inducible stem cell potential, expressing both ALDH and CD133 following culturing in stem cell medium. This potential CSC population, which makes up for 0, 1-1, 7% of the cells, displayed increased self-renewing abilities and increased tumourigenicity, giving tumours in vivo from as few as 100 injected cells

Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3351708
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. A: More than markers: biological significance of cancer stem cell-defining molecules.
    2. (2009). al: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res
    3. al: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.
    4. (2009). al: Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol
    5. (2007). al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell
    6. al: ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome.
    7. (2007). al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell
    8. (2008). al: Detection and characterization of CD133+ cancer stem cells in human solid tumors. PLoS One
    9. al: Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5:e10277.
    10. (2007). al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell
    11. (2007). al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology
    12. (2007). al: Identification and expansion of human colon-cancer-initiating cells. Nature
    13. (2006). al: Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA
    14. (2005). al: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/ progenitor cell properties. Cancer Res
    15. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.
    16. (2009). Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun
    17. (2008). Alison MR: CD133: molecule of the moment.
    18. (2000). Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol
    19. (2009). D: ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev
    20. (1997). et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood
    21. (2009). et al: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res
    22. (2008). et al: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res
    23. (2009). et al: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res
    24. et al: CD133 expression in chemo-resistant Ewing sarcoma cells.
    25. et al: Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo.
    26. (2003). et al: Identification of a cancer stem cell in human brain tumors. Cancer Res
    27. (2009). et al: Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res
    28. (2004). et al: Identification of human brain tumour initiating cells. Nature
    29. (2006). et al: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell
    30. (1988). Fenselau C: Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Adv Enzyme Regul
    31. (2011). FGF signalling as a mediator of lineage transitions–evidence from embryonic stem cell differentiation. J Cell Biochem 110:10-20. Stratford et al. Clinical Sarcoma Research
    32. (2009). GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. Int Immunol
    33. (2007). JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature
    34. (2008). JP: Cancer stem cells - old concepts, new insights. Cell Death Differ
    35. (2003). MF: Prospective identification of tumorigenic breast cancer cells.
    36. (1989). OM: The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Prog Clin Biol Res
    37. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity.
    38. (2007). Squire JA: Stem cell enrichment approaches. Semin Cancer Biol
    39. (2007). Stem cell-like cancer cells in cancer cell lines. Cancer Biomark
    40. T: Expression of CD133 in synovial sarcoma.
    41. (2008). The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    42. Understanding the cancer stem cell.
    43. (2009). Wu PY: CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.